Corporate News

Medicilon’s Formulation CDMO Platform Advances Taiji Group’s Next-Generation RNA Polymerase Inhibitor DSC158A Tablets to Clinical Stage
TPD CN-US Dual Filing Milestone: Medicilon’s One-Stop Platform Helps Gluetacs Secure Dual Approval for GT818, a First-in-Class RSK Degrader
World’s First Long-Acting Anti-RSV Monoclonal Antibody Xinduotuo Wins NMPA Approval — Medicilon Empower Trinomab’s Source Innovation
Novel Analgesic Breakthrough: Xinhua Pharmaceutical’s Class 1 Drug LXH-2103 Secures Clinical Approval with Medicilon’s Preclinical Support
Medicilon Empowers IxCell’s IxCell PB-ZRAK Injection to Secure Clinical Trial Approval for Advanced Hepatocellular Carcinoma
Medicilon Delivers One Stop Preclinical Support as Yizhong Pharma Secures NMPA Clinical Approval for YXC‑001 Tri‑functional Antibody Fusion Protein and YXC‑002 4th‑Generation EGFR Kinase Inhibitor

Events

EFMC-ISMC 2026
4th SMC and AimedBio ADC Conference
ACS Fall 2026
【BRIDGE】Medicilon XDC Innovation Forum · Seoul 2026
Medicilon Webinar | IND-enabling Toxicity Studies, CTD Documentation and Translational Cardiac Risk Assessment
RACI Congress 2026

Medicilon Academy

【Case Study】New Approach Methods NAMs
【Case Study】Route, Solid-State, and Impurity Optimization (Small-Molecule API)
【Case Study】IND Completion in 12 Months (Small-Molecule NCE)
Boston Non-Tumor Models Innovation
【White Paper】Navigating the DMPK Gauntlet: A Strategic Analysis of the Interconnected Challenges Shaping the Future of Drug Development
【White Paper】Patient-Derived Xenograft Organoids: Advancements and Applications in Precision Oncology

Digital Materials

A Sensitive LC–MS Bioanalytical Method for Simultaneous Quantification of Structurally Similar Cyclic Tetrapeptides at the Picogram Level (Download)
Quantification of antibody-Conjugated Drug in Cleavable ADCs: A Universal, Automated, and Cost-Effective LC-MS/MS Platform (Download)
Leveraging a Humanized SLE Mouse Model to Evaluate Next-Generation Immune-Cell-Targeted Therapeutics (Download)
Integrated Mass Spectrometric Workflows Enabling Next-Generation Conjugate Therapeutics in Cancer Research (Download)
From Sequence Design to AOC Production Medicilon’ s End-to-End RNAi Development Platform (Download)
Developing PDX-Derived Organoid Models for Efficacy Evaluation of Anticancer Therapies (Download)

Search Medicilon

Preclinical CRO

Medicilon’s Formulation CDMO Platform Advances Taiji Group’s Next-Generation RNA Polymerase Inhibitor DSC158A Tablets to Clinical Stage

Preclinical CRO

TPD CN-US Dual Filing Milestone: Medicilon’s One-Stop Platform Helps Gluetacs Secure Dual Approval for GT818, a First-in-Class RSK Degrader

Preclinical CRO

World’s First Long-Acting Anti-RSV Monoclonal Antibody Xinduotuo Wins NMPA Approval — Medicilon Empower Trinomab’s Source Innovation

Contact Medicilon

Name(Required)
Address(Required)